A cloud-based decision support solution for diagnostic and prognostication of prostate cancer

News - December 2016

Uppsala University Holding AB buys shares in CADESS Medical AB.

Uppsala, Sweden - December 20, 2016 – CADESS Medical AB, a leader in digital pathology analytics for the diagnosis and prognostication of prostate cancer, today announced that Uppsala University Holding purchased shares in the company. The proceeds are going to be used to further develop CADESS Medical’s innovative and unique digital imaging solution consisting of a new staining protocol and algorithm that can recognize prostate cancer and determine the malignancy grade according to the Gleason grading system.

“The raised capital will help us to move our project ahead and proves the quality of our research and development efforts at CADESS Medical”, said Ingrid Carlbom, Professor Emeritus and CTO at CADESS Medical. She continued, “we have several great research programs in the pipe-line aimed at deepening and broadening our technology, as well as getting it closer to commercialization”. “The capital injection will improve both speed and quality in the development of the company and our technology”, said Johan von Heijne, Executive Advisor and responsible for the company’s investor relations.

The funding will be used to further speed up the development of CADESS Medical and its innovative and unique digital imaging solution consisting of a new staining protocol and algorithm that can recognize prostate cancer and determine the malignancy grade according to the Gleason grading system.

The funding is very welcome and proofs the potential and quality of the patented and unique imaging technology developed by CADESS Medical. “We are very happy to receive additional funding enabling us to focus even further on the development towards a commercial product that will help pathologists, urologists to combat prostate cancer, patients by reducing unnecessary treatment, and healthcare providers by increasing efficiency and reducing costs”, commented Professor Ingrid Carlbom, CTO at CADESS Medical.

About CADESS Medical AB

CADESS Medical AB is a Swedish medical analytics company offering CADESS™, a cloud-based innovative digital pathology decision support solution based on image analysis for diagnosis and prognostication of cancer intended to improve patient outcome and reduce healthcare costs for prostate cancer. CADESS is the result of ten years of research at the Centre for Image Analysis, Department of Information Technology at Uppsala University, in collaboration with Uppsala University Hospital. For more information see www.cadessmedical.com.


For Further information, please contact:

Ingrid Carlbom, Chief Technology Officer
Tel: +46 (0) 73 048 20 25
E-mail: ingrid.carlbom@cadessmedical.com

Johan von Heijne, Investor Relations and Executive Advisor
Tel: +46 705 95 15 10
E-mail: johan.vonheijne@cadessmedical.com